What is Abeomics?
Abeomics is a biotechnology company specializing in the provision of a comprehensive suite of research products, including antibodies, engineered cell lines, assay kits, and proteins. The company extends its expertise to critical services such as drug screening, stable cell line development, and custom antibody development. These offerings are meticulously designed to expedite research across diverse fields, including immunology, oncology, and infectious diseases. Abeomics primarily serves the pharmaceutical and research sectors, delivering high-quality reagents and bespoke solutions. Their commitment to innovation is further demonstrated through their development of recombinant biosimilar antibodies and a variety of kits tailored for molecular biology applications.
How much funding has Abeomics raised?
Abeomics has raised a total of $43K across 1 funding round:
Debt
$43K
Debt (2021): $43K with participation from PPP
Key Investors in Abeomics
PPP
Public-Private Partnership
What's next for Abeomics?
With significant Series B/C stage funding, Abeomics is poised for strategic scaling and enhanced research and development initiatives. The recent influx of substantial expansion capital is expected to fuel advancements in their product pipeline and service offerings, potentially leading to new therapeutic discoveries and broader market reach. This strategic investment will likely enable Abeomics to fortify its position as a key player in the biotechnology research supply chain, driving innovation in drug discovery and diagnostics.
See full Abeomics company page
